. 2019 Aug 25;74(12):3565–3572. doi: 10.1093/jac/dkz357

Table 1.

Characteristics of included patients, their treatment and CSF concentrations of aciclovir (ACV) and CMMG at all sampling timepoints

Patient	Age (years)	Gender	Weight (kg)	Indication for treatment	ACV dose q8h (mg/kg)	Lag time from dose to sampling (h)	Treatment duration (days)	Estimated CL_CR (mL/min)	RIFLE	Serum concentration (μmol/L)		CSF concentration (μmol/L)		CSF:serum albumin ratio×10^-3	Neuropsychiatric symptoms during treatment
Patient	Age (years)	Gender	Weight (kg)	Indication for treatment	ACV dose q8h (mg/kg)	Lag time from dose to sampling (h)	Treatment duration (days)	Estimated CL_CR (mL/min)	RIFLE	ACV	CMMG	ACV	CMMG	CSF:serum albumin ratio×10^-3	Neuropsychiatric symptoms during treatment
1^a	70	M	56	herpes encephalitis	10	7.5	13	80	R	5.7	0.74	8.4	0.15	N/A
1^b					10	9	20	71		2.7	0.29	7.1	<0.15	15.4
1^c					10	8.5	27	57		5	0.59	8.5	<0.15	11.7
2	79	F	52	herpes encephalitis	11	6.5	9	61	R	70	12	11	0.27	7
3	66	M	89	suspected varicella meningitis	1000^d	1	14	84	F	29	1.7	3.1	<0.15	6.9
4^a	35	M	98	herpes encephalitis	15	6	2	30	F	110	57	40	3.3	29.4	confusion, improved at dose adjustment
4^b					12	7.5	9	125		25	2.8	7.5	0.15	15.7
4^c					12	8	16	149		10	1.5	10	0.19	23.8
5	30	M	100	suspected encephalitis	10	6	3	109		9.6	1.3	6.7	<0.15	24.3
6^a	64	F	60	herpes encephalitis	12	3.5	3	40	R	50	9.7	24	0.68	20.1	confusion, improved at end of treatment
6^b					12	4	13	65		18.6	2.7	14	0.3	15.4
6^c					12	8	21	70		11	2.3	12	0.23	11.9
7^a	65	M	76	recurrent herpes encephalitis	15	2.5	8	109	I	55	18	16	0.29	14.7	confusion, improved at end of treatment
7^b					15	4.5	15	51		120	38	29	1	10.5
7^c					15	21	29	35		11	11	8.2	0.66	14.6
8	55	M	77	herpes encephalitis	10	5.5	13	122		11	1	6.7	<0.15	7.4
9^a	58	M	68	stroke	11	1	5	56		75	10	12	0.27	9.3
9^b					10	6.5	11	52		20	5	11	0.26	11.7
10	40	M	120	herpes meningoencephalitis	10	1	12	184		13	0.9	8.5	<0.15	9.6
11	41	F	67	herpes meningitis	10	4.5	7	117		14	1.5	17	0.77	26.7
12	67	M	78	suspected encephalitis	9	1.5	5	87		31	4.9	8.9	0.17	13.8
13	26	F	50	suspected encephalitis	15	8	3	119		6.1	1.2	5.9	<0.15	8.6
14	58	M	87	herpes meningitis	1000^d	1	10^e	115		13	2	4.8	<0.15	8.6
15^a	65	F	67	herpes encephalitis	9	6	6	73		10	2.3	7.7	0.16	8.5
15^b					9	3	11	79		40	5.4	7.6	<0.15	8.8
16	39	F	77	herpes encephalitis	14	1	13	131		N/A	N/A	8	<0.15	22.5
17	49	F	72	herpes meningitis	9	1.5	3	129		17	1.6	7.5	<0.15	4.1
18	53	M	85	varicella meningitis	14	5.5	2	123		N/A	N/A	14	0.24	13.3
19^a	75	F	57	varicella encephalitis	10	7	7	54	R^f	15	5.2	28	6.4	162.4	confusion, improved at end of treatment
19^b					10	7	14	68		13	3.6	27	3.8	108.1	confusion, improved at end of treatment
20^a	55	F	68	Ramsay Hunt syndrome	14	2.5	2	131	F	31	3.8	6.5	<0.15	1.7	anxiety, improved slowly at end of treatment
20^b					5	3	9	60		12	3	3.3	<0.15	1.4	anxiety, improved slowly at end of treatment
21^a	38	M	81	varicella encephalitis	14	4.5	1	141		9.9	1.1	12	0.2	28.8
21^b					14	2.5	3	135		19	1.9	14	0.24	18

ACV dose, mg iv aciclovir per kg body weight in a single dose, administered three times daily, except in patient 20^b, where doses were administered twice daily; N/A, not available; M, male; F, female; (RIFLE column) R, risk; I, injury; F, failure; shaded areas indicate patients assessed to have AINS.

First sampling in patient where repeated sampling was performed.

Second sampling.

Third sampling.

Treatment with oral valaciclovir in single dose (mg), three times daily.

Patient had previously received valaciclovir in a lower dose regimen as prophylaxis.

Patient did not fulfil RIFLE criteria based on creatinine, but calculation of GFR according to cystatin C CAPA estimated GFR at 30 mL/min, corresponding to at least risk of acute kidney failure.